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A B S T R A C T
Many psychoactive substances affect the human dopamine (DA) reuptake transporter (hDAT). Polymorphisms in
the encoding gene could affect the functionality of the transporter and consequently alter effects of psychotropic
and recreational drugs. Recently, a T356M single nucleotide polymorphism in the human SLC6A3 gene was
described, which resulted in functional impairments of DA uptake. Therefore, we investigated the effects of 10
psychoactive substances (0.01–1000 μM)) on DA uptake in human embryonic kidney (HEK) 293 cells transiently
overexpressing wildtype (WT) or T356M hDAT.
Our data shows that T356M hDAT has a 3 times lower Vmax and a 3 times higher Km compared to WT hDAT.
Additionally, all psychoactive substances inhibited DA uptake by T356M and WT hDAT. The DA reuptake in-
hibitors (methylphenidate, cocaine, and bupropion) inhibited DA uptake by WT hDAT most potently, followed
by amphetamine-type stimulants [4-fluoroamphetamine (4-FA), amphetamine and MDMA], selective serotonin
reuptake inhibitors (SSRI; fluoxetine and citalopram) and arylcyclohexylamines [methoxetamine (MXE) and
ketamine].
Compared to DA uptake by WT hDAT, bupropion, methylphenidate, cocaine, and MXE less potently inhibited
DA uptake by T356M hDAT, while citalopram more potently inhibited uptake. The differences in IC50 values
between T356M and WT hDAT were considerable (3–45 fold). As such, the presence of this polymorphism could
affect treatment efficiency with these substances as well as susceptibly for toxicity and addiction for individuals
carrying this polymorphism.
1. Introduction
Over half of the adult American population uses at least one pre-
scription drug and 1 in 7 is considered a polydrug user (≥5 different
prescription drugs). Many of these prescription drugs involve psycho-
tropic medication. Of the psychotropic drug users, the majority uses
antidepressants (13%), followed by anxiolytics, sedatives, and hypno-
tics (6%) (Kantor et al., 2015). In addition to a significant proportion of
the population being exposed to prescribed psychotropic drugs, ex-
posure to other psychoactive compounds is also of relevance. An esti-
mated 25% of the adults (15–64 years) in the European Union have
used illicit drugs at least once during their life-time (EMCDDA, 2018).
Although (prescribed or illicit) psychoactive compounds likely have
multiple mechanisms of action, their effects are at least partly attribu-
table to increased concentrations of monoamine neurotransmitters in
the brain. This increase in monoamines is caused by the inhibition of
neurotransmitter reuptake via inhibition of the dopamine (DA), nor-
epinephrine (NE) or serotonin (5-HT) reuptake transporters (DAT, NET,
and SERT). Moreover, several amphetamine-type stimulants are trans-
porter substrates and trigger a transporter-mediated release of mono-
amines (transporter reversal), resulting in additional monoamine re-
lease (Seger, 2010; Torres et al., 2003). Such increases of monoamine
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concentrations can modulate the activity of postsynaptic neuro-
transmitter receptors (Torres et al., 2003; Volkow et al., 2006) and
trigger both favourable and adverse effects. With the emergence of over
700 new psychoactive substances (NPS)(UNODC, 2018), many sub-
stances have entered the drug market that can affect neurotransmitter
reuptake transporters (Zwartsen et al., 2017).
Of the three monoamine reuptake transporters, DAT is a primary
site of action for many psychoactive substances [for review see
(Hondebrink et al., 2018; Zhu and Reith, 2008)]. Disturbed DAT
function is implicated in many neurodegenerative and neuropsychiatric
disorders like Parkinson’s disease, attention deficit hyperactivity dis-
order (ADHD), depression and addictive disorders (Blum et al., 2013;
Dunlop and Nemeroff, 2007; Madras et al., 2005; Nutt et al., 2004). As
DAT is coded by a single copy gene (SLC6A3), with its expression
mostly restricted to the dopaminergic system, it suggests limited op-
portunity for compensation by other gene products. Therefore, poly-
morphisms in this gene could have a potentially large impact (Hahn and
Blakely, 2002).
Recently, others have described a rare de novo hDAT mutation in an
autism spectrum disorder patient (Neale et al., 2012). This mutation
caused a single nucleotide polymorphism (SNP) in which threonine
(Thr) 356 has been substituted by methionine (Met) (T356M) in the 7th
transmembrane domain of hDAT. As this SNP resides in a highly con-
served region implicated in ion binding, hDAT containing the T356M
mutation was suspected to functionally differ from wild type (WT)
hDAT (Hamilton et al., 2013). Recent research demonstrated that
T356M hDAT indeed has a ˜3-fold reduced affinity for DA and a ˜2.5-
fold reduction in maximum uptake velocity compared to WT hDAT
(Herborg et al., 2018). Interestingly, IC50 values of methylphenidate,
cocaine, and amphetamine are also higher in T356M hDAT (Herborg
et al., 2018). The differences in IC50 were particularly pronounced for
methylphenidate and cocaine, which are considered as specific DAT
blockers. The difference in IC50 was less striking for amphetamine,
which in addition to being a DAT blocker, is also known as a DAT re-
verser [Herborg et al. (2018); for review on modes of action see
Hondebrink et al. (2018)].
To confirm and extend on these observations, we selected 10 psy-
choactive substances (including therapeutic substances and recrea-
tional drugs) from several classes to further investigate the functionality
of T356M hDAT in the presence of psychoactive substances. To this
end, we transiently expressed the T356M polymorphic and WT hDAT in
HEK293 cells and compared the inhibitory potencies of the selected
psychoactive compounds.
2. Materials and methods
2.1. Substrates and psychoactive substances
[3H]DA (63.6 Ci/mmol) was purchased from PerkinElmer
(Groningen, The Netherlands). DA, bupropion hydrochloride [2-(tert-
butylamino)-1-(3-chlorophenyl)propan-1-one;hydrochloride], fluox-
etine hydrochloride [N-methyl-3-phenyl-3-(4-(trifluoromethyl)phe-
noxy)propan-1-amine;hydrochloride] and citalopram hydrobromide [1-
(3-(dimethylamino)propyl)-1-(4-fluorophenyl)3H-2-benzofuran-5-car-
bonitrile;hydrobromide] were purchased from Sigma-Aldrich (St Louis,
MO, USA). Cocaine [methyl(1S,3S,4R,5R)-3-benzoloxy-8-methyl-8-
azabicyclo(3.2.1)octane-4-carboxylate], DL-amphetamine (1-phenyl-
propan-2-amine) and methylphenidate (methyl-2-phenyl-2-piperidin-2-
ylacetate) hydrochloride (purity> 98.5%) were obtained from Spruyt
Hillen (IJsselstein, the Netherlands). MDMA [3,4-methylenedioxy-N-
methamphetamine, 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-
amine], 4-FA [4-fluoroamphetamine, 1-(4-fluorophenyl)-propan-2-
amine] and methoxetamine [MXE; 2-(ethylamino)-2-(3-methox-
yphenyl)cyclohexan-1-one] hydrochloride (purity> 97%) were ob-
tained from Lipomed (Weil am Rhein, Germany). (S)-Ketamine
[Ketanest-S; (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-
one] was obtained from Eurocept Pharmaceuticals (Ankeveen, the
Netherlands). Drug stock solutions (10mM) were prepared daily in
Hank’s Balanced Salt Solution (1X) (HBSS) buffer solution (Catalog #
14025; Thermo Fisher, Breda, The Netherlands), and 10mM HEPES
(HBSS-HEPES, pH 7.4), with [3H]DA and DA.
2.2. Cloning of (T356M) hDAT
The neurotransmitter transporter SLC6A3 (hDAT; accession number
NM_001044.4) was cloned into a pENTR4 vector at the BamHI and XhoI
sites which introduces a 10 amino acid tag at the N-terminal side of the
protein (GenScript, Piscataway, NJ, USA). The T356M polymorphism
was introduced using polymerase chain reaction (PCR) (primer se-
quence can be found in Supplemental Fig. 2) followed by DpnI diges-
tion. After transformation into DH5α cells clones were picked. After
sequencing of the clones, pENTR4-SLC6A3 WT and T356M were con-
firmed. The SLC6A3 gene was cloned into the destination vector
(BacMam) using a Gateway® LR-reaction (Invitrogen™, Carlsbad, CA,
USA) as described before (El-Sheikh et al., 2007). The expression clone
was transformed into DH10Bac E.coli. For both WT and T356M hDAT,
three different bacterial colonies were used to isolate three stocks of
recombinant bacmid DNA. Next, Sf9 cells were transfected with these
bacmids and supernatant was used to generate the viral stocks. Three
different WT and T356M viruses were created to get an independent
n=3. The three viruses were used each experiment.
2.3. Transient expression in HEK293 cells
Human Embryonic Kidney 293 (HEK293) cells were used to express
WT and T356M hDAT as they are a commonly used overexpression
model for (transport) proteins (Thomas and Smart, 2005). These cells
are of human origin and have, in general, a low background transport
activity (Supplemental Fig. 1; Zwartsen et al., 2017). In addition, they
are easily transduced with recombinant baculovirus, making them
suitable for the WT and T356M hDAT transfection.
With some minor deviations, cells were maintained and transduced
as described by te Brake et al. (te Brake et al., 2016). Briefly, HEK293
cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM)
high glutamax (Thermo Fisher) with 10% (v/v) foetal calf serum (FCS).
Cells were seeded on a biocoat poly-D-lysine plate, (VWR International,
Amsterdam, The Netherlands) at 120,000 and 20,000 cells/well for a
24-wells and 96-wells plate, respectively. After 24 h, cells were trans-
duced with virus (10% of end volume) and sodium butyrate (2mM
final) was added. Cells transduced with mock virus (enhanced yellow
fluorescent protein (EYFP) instead of hDAT cDNA) were used to de-
termine non-specific uptake. Cells were then incubated at 37 °C for
48–72 h.
2.4. WT and T356M hDAT uptake assay
Transport and inhibition experiments were performed as described
by te Brake et al. (2016). Briefly, on the day of the experiment, the
culture medium was removed and cells were washed with 37 °C HBSS-
HEPES buffer. Uptake was initiated by replacing this solution with 37 °C
HBSS-HEPES buffer supplemented with [3H]DA and DA, with or
without an inhibitor. Uptake was terminated by washing with ice-cold
HBSS-HEPES buffer containing 0.5% (m/v) bovine serum albumin
(BSA), after which the cells were washed with ice-cold HBSS-HEPES
buffer and lysed with NaOH (1M). Next, samples were transferred to
scintillation vials before adding liquid scintillation fluid (PerkinElmer,
Waltham, MA, USA). In all experiments, reference samples of the [3H]
DA stocks were taken. Radioactivity was measured using the Packard
TriCarb™ liquid scintillation analyser (2900 TR; PerkinElmer). In ad-
dition, the protein amount was determined using Bio-Rad Protein Assay
Dye Reagent (Bio-Rad Laboratories, Veenendaal, The Netherlands) to
estimate the number of cells per condition.
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To test for the optimal incubation time, mock virus and WT hDAT
transduced HEK293 cells in 24-wells plates were incubated with
7.85 nM [3H]DA for different time periods (1, 2, 5 and 10min). Based
on these data, all subsequent experiments were performed using 2min
incubation time (Supplemental Fig. 1). To determine the maximum
velocity of uptake (Vmax) and the Michaelis-Menten constant (Km) of
WT hDAT and the T356M polymorphism, cells were incubated with a
constant concentration of 14.1 nM [3H]DA with or without supple-
mentation of a range of DA (0.03 μM – 300 μM). To determine the
uptake of DA by the WT hDAT and the T356M polymorphism during
co-incubation with psychoactive substances, cells were incubated with
a constant concentration of 1.0 μM DA and 7.85 nM [3H]DA and a range
of inhibitor concentrations. Effects of methylphenidate and bupropion
were measured at final concentrations of 0.03–1000 μM, whereas for all
other compounds effects were measured at final concentrations of
0.01–1000 μM. Tested concentrations were based on concentrations
relevant to human exposure.
2.5. Calculation of kinetics and inhibition assays
For the uptake kinetics and the inhibition assays, transport was
expressed as pmol/mg protein/min. Uptake via WT and T356M hDAT
was corrected for the mock transporter uptake on the same plate at
corresponding concentrations (2 wells per concentration or vehicle).
The number of viruses used (nvirus; technical replicates; one or two wells
per virus per exposure), the number of experiments performed (Nplates;
biological replicates) and the total number of wells per type of assay are
listed in the legends of the figures.
To determine the Vmax, and Km, the Michaelis-Menten equation was
fitted to the uptake values using non-linear regression analysis
(GraphPad Prism™ version 7.04; GraphPad Software Inc., La Jolla, CA,
USA).
To determine the inhibition of DA uptake, technical replicates were
normalized to the virus and plate matched control (vehicle-exposed
cells). Next, the technical replicates per concentration and vehicle were
pooled for each experiment. After that, pooled technical replicates of
the three experiments were averaged. Non-linear regression analysis
was used to calculate IC50 values with GraphPad Prism, and if needed a
bottom=0 constraint was added.
Statistical analyses were performed with one-way ANOVA’s fol-
lowed by a Dunnet’s post-hoc test to compare the Km, Vmax and IC50
values between hDAT and T356M (p < 0.05). IC50 values are pre-
sented with 95% confidence intervals [CI] of nviruses and Nplates. Data
points and Km and Vmax values are shown as the mean ± standard
error of the mean (SEM) for nviruses and Nplates. Analysed and raw data
available upon request.
2.6. Calculation of the estimated human brain concentration
The estimated human brain concentration range was calculated for
bupropion, citalopram, and methylphenidate according to Zwartsen
et al. (2017). Estimated human brain concentrations of other substances
were obtained from literature (Hondebrink et al., 2018; Zwartsen et al.,
2018, 2017).
For bupropion, the human blood concentration range between
0.06−0.7 μM was established based on volunteer studies (Hoiseth
et al., 2015; Jefferson et al., 2005; Johnston et al., 2002; Park et al.,
2010; Posner et al., 1984; Viviani et al., 2012). This range was multi-
plied by the brain partitioning factor (BPF) (2.0–9.8), which was based
on blood and brain concentrations reported in animal studies (Butz
et al., 1982; DeVane et al., 1986; Suckow et al., 1986) to derive an
estimated human brain concentration for bupropion that ranges from
0.1 to 6.7 μM.
The estimated human brain concentration for citalopram was esti-
mated to range from 0.03–7.4 μM. This was based on human blood and
serum concentrations of patients using citalopram and people arrested
for driving under the influence of drugs [0.03–1.1 μM (Jones et al.,
2016; Ostad Haji et al., 2011; Paulzen et al., 2016; Senna et al., 2010)],
multiplied by the BPF of 1.0–6.7 [obtained from human lethal case
reports (Fu et al., 2000; Luchini et al., 2005; Mari et al., 2012; Nedahl
et al., 2018; Rohrig and Hicks, 2015; Wille et al., 2009)].
For methylphenidate, human plasma concentrations ranging be-
tween 0.02 and 0.5 μM were found in volunteer studies (Chan et al.,
1980; Gualtieri et al., 1982; Modi et al., 2000; Volkow et al., 2003).
Based on mice studies, a BPF of 1.0–13 (Balcioglu et al., 2009) was used
to estimate the human brain concentration of methylphenidate of
0.02–6.5 μM.
3. Results
3.1. Transport of the WT and T356M polymorphic hDAT
The T356M polymorphic hDAT variant was successfully generated
and expressed in HEK293 cells. Transport activity of the WT hDAT and
T356M hDAT variant was measured at the predetermined optimal in-
cubation time of 2min (Supplemental Fig. 1).
To determine the uptake kinetics of WT and T356M hDAT, cells
transduced with the respective transporters were incubated with dif-
ferent concentrations of DA (0.02–300 μM), at a constant concentration
of [3H]DA (14 nM). The Vmax of the WT hDAT was 1381 ± 97 pmol/
mg protein/min, which was 2.8 times higher than the Vmax of
493 ± 21 pmol/mg protein/min determined for T356M (Fig. 1,
p < 0.001). Km values also differed significantly with values for WT
hDAT of 8.8 ± 0.5 μM and T356M hDAT of 26.4 ± 3.1 μM
(p < 0.01).
3.2. Inhibition of the WT and T356M polymorphic hDAT by psychoactive
substances
To determine the inhibitory potency of psychoactive substances,
both the T356M and the WT hDAT were exposed to a set of 10 sub-
stances, consisting of potent DA reuptake inhibitors (methylphenidate,
cocaine and bupropion), DAT substrates that reverse DA transport
(amphetamine, MDMA and 4-FA), selective serotonin reuptake in-
hibitors (SSRI) with low affinity for DAT (citalopram and fluoxetine)
and arylcyclohexylamines with limited DAT inhibitory properties (ke-
tamine and MXE)(Hondebrink et al., 2018; Korte et al., 2015; Zwartsen
et al., 2017) (Fig. 2). In all cases, exposure to these substances con-
centration-dependently inhibited the uptake of DA. In 4 out of 10 drugs,
a difference was observed between the inhibition of uptake via the WT
and the T356M hDAT.
Fig. 1. Dopamine uptake of WT and T356M polymorphic hDAT. Uptake at
different dopamine (DA) concentrations (t= 2min) was measured as mean
pmol/mg protein/min ± SEM for a total of 12 wells (Nplates= 3, nviruses= 2).
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3.2.1. Therapeutic drugs
Fluoxetine, bupropion, methylphenidate, and citalopram con-
centration-dependently inhibited the uptake of DA via the WT and the
T356M polymorphic hDAT (Fig. 3). The WT transporter was inhibited
with IC50 values of 68, 4.0, 0.4 and 203 μM, respectively (Table 1). The
inhibition of DA uptake via T356M did not differ significantly from WT
when exposed to fluoxetine [WT vs MT: 45 μM vs 68 μM (p=0.26)].
The IC50 values of both bupropion and methylphenidate were sig-
nificantly increased by the T356M polymorphism [WT vs MT: 4.0 μM
vs 30 μM (p < 0.001) and 0.4 μM vs 20 μM (p < 0.001), respectively].
This increase in IC50 values was 7.5-fold for bupropion and 45-fold for
methylphenidate. Notably, citalopram inhibited the T356M poly-
morphic hDAT with a significant 3-fold higher potency compared to WT
hDAT [WT vs MT: 203 μM vs 67 μM (p=0.008)].
3.2.2. Recreational drugs
As with the therapeutic drugs, all recreational drugs concentration-
dependently inhibited DA uptake via WT and T356M polymorphic
hDAT (Figs. 4 and 5). The amphetamine-type stimulants MDMA, am-
phetamine and 4-FA all inhibited WT transporters with comparable IC50
values (Fig. 4). Interestingly, IC50 values for inhibition of DA uptake
were also comparable between the WT and T356M hDAT (Table 1; WT
vs MT): 34 μM vs 11 μM (p=0.08) (MDMA), 11 μM vs 11 μM (p=1.0)
(amphetamine), and 11 μM vs 7.0 μM (p=0.2) (4-FA).
As depicted in Fig. 5, the IC50 values of the arylcyclohexylamine
ketamine were 10–80 times higher than those of amphetamine-type
stimulants and were also comparable between the WT and T356M
hDAT (Table 1; WT vs MT): 383 μM vs 476 μM (p=0.3). The ketamine
derivative MXE inhibited T356M hDAT less potently than WT hDAT: a
˜4-fold difference in IC50 values was observed [WT vs MT: 108 μM vs
404 μM (p=0.0003)]. Cocaine is a potent DA reuptake inhibitor in WT
Fig. 2. Chemical structures of the tested therapeutic (fluoxetine, bupropion, methylphenidate, and citalopram) and recreational drugs (cocaine, amphetamine, 4-FA,
MDMA, ketamine and MXE).
Fig. 3. Concentration-response curves for the inhibition of dopamine uptake via
WT (A) and T356M polymorphic hDAT (B) for different therapeutic drugs.
Depicted are fluoxetine, bupropion, methylphenidate, and citalopram. Uptake
is depicted as mean ± SEM for a total of 9 wells (Nplates= 3, nviruses= 3)], as a
percentage of control. IC50 values are listed in Table 1.
Fig. 4. Concentration-response curves for amphetamine-type stimulants for the
inhibition of dopamine uptake via WT (A) and T356M polymorphic hDAT (B).
Depicted are amphetamine-type stimulants MDMA, amphetamine and 4-FA.
Uptake is depicted as mean ± SEM for a total of 9 wells (Nplates= 3,
nviruses= 3), as a percentage of control. IC50 values are listed in Table 1.
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hDAT (IC50 value of 1.1 μM). However, the T356M polymorphism in-
creased the IC50 value of cocaine to inhibit DA uptake by ˜21-fold
[Table 1; 23 μM (p < 0.001)].
4. Discussion
Over the last decade, research into the pharmacological effects of
polymorphisms and mutations in targets of psychoactive substances has
gained interest. The current study extends on the earlier observation
that T356M hDAT impairs DA uptake and alters sensitivity to certain
psychoactive substances (Herborg et al., 2018).
Our results confirm the functional alterations in T356M hDAT
compared to WT hDAT (Fig. 1), and also indicate differences in the
potency of various groups of psychoactive substances to inhibit hDAT.
We found a statistically significant decrease in Vmax and an increase in
Km for T356M hDAT, in line with both Herborg et al. (2018) and
Hamilton et al. (2013). The Km value determined for WT hDAT is in the
range of values reported by others using the same cell line at 37 °C
(Moron et al., 2003; Riherd et al., 2008; Storch et al., 1999; Yoon et al.,
2009), whilst the Vmax for WT hDAT observed in this study is ˜2-fold
higher than reported by others (Moron et al., 2003; Storch et al., 1999),
which may be due to differences in experimental setup, like incubation
time (Scholze et al., 2001).
IC50 values of WT hDAT DA uptake for amphetamine, cocaine, and
methylphenidate determined by Herborg et al. (2018) are ˜10-fold
lower compared to our study, possibly due to the use of different
transfected cells (COS-7) and measurements at room temperature.
However, our IC50 values for inhibition of WT hDAT of amphetamine,
4-FA, MDMA, cocaine, MXE, fluoxetine, methylphenidate, and bupro-
pion are comparable with other studies measuring DA uptake at 37 °C in
HEK293 cells [for review see Table 3 in Zwartsen et al., 2017; Simmler
et al (2013)].
Notably, the differences in inhibition of DA uptake (T356M vs WT
hDAT) by the potent DA reuptake inhibitors methylphenidate and co-
caine (Figs. 3 and 5) are similar between our data and Herborg et al
Fig. 5. Concentration-response curves for arylcyclohexylamines and cocaine for
the inhibition of dopamine uptake via WT (A) and T356M polymorphic hDAT
(B). Depicted are arylcyclohexylamines ketamine and methoxetamine (MXE)
and cocaine. Uptake is depicted as mean ± SEM for a total of 9 wells
(Nplates= 3, nviruses= 3), as a percentage of control. IC50 values are listed in
Table 1.
Table 1
IC50 values for the inhibition of WT and T356M polymorphic hDAT by psychoactive drugs compared to the estimated human brain
concentration [brain]. IC50 values (μM) are presented with 95% confidence intervals [CI]. * and ** indicate that T356M hDAT IC50
values are significantly (p < 0.01, p < 0.001, respectively) different from WT. IC50 values of WT and T356M hDAT which are> 2
times the estimated human brain concentration (μM) are highlighted in grey. a (Zwartsen et al., 2017); b (Hondebrink et al., 2018); c
(Zwartsen et al., 2018).
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(2018). Additionally, our data show for the first time that bupropion
inhibited DA uptake by T356M hDAT less potently compared to the
potent inhibition of WT hDAT (Fig. 3). Interestingly, citalopram in-
hibited the DA uptake via the T356M polymorphic hDAT more potently
compared to WT hDAT.
These findings are of interest as heterogeneity of the response of
individuals to prescribed psychotropic drugs and (illicit) recreational
drugs has been a concern from a pharmacological and toxicological
point of view for decades (Keers and Aitchison, 2011; Narasimhan and
Lohoff, 2012; Rietjens et al., 2012). It is known that interindividual
variation is at least partially due to genetic factors. While it is re-
cognized that pharmacokinetics can differ significantly between pa-
tients, the role of genetic differences in pharmaco- and toxicodynamics
has been hardly investigated, even though differences in expression
and/or function of receptors, ion channels or transporters could also
alter drug effects.
As the investigated polymorphism was discovered only in one pa-
tient during screening of autism spectrum disorder (ASD) patients and
their parents, it is not yet possible to estimate the prevalence of this
polymorphism in the human population. Future screening of different
and larger populations could show a higher prevalence of the T356M
polymorphism. In this case, these findings are of particular relevance as
many people are exposed to psychoactive substances (therapeutics and/
or drugs of abuse). The effect of the T356M polymorphism, even
though likely not highly prevalent in the human population, also il-
lustrates the need for wider genome screens in the search for other
hDAT polymorphisms, as such mutations can also add to the inter-
individual variation in response to psychoactive substances.
Patients with this polymorphic transporter may be classified as
treatment-resistant for bupropion or methylphenidate. Although WT
hDAT is inhibited by bupropion and methylphenidate at estimated
therapeutic brain concentrations (IC50 values for hDAT within esti-
mated brain concentration; Table 1), T356M hDAT is not (IC50 values
for hDAT above estimated brain concentration), possibly contributing
to the interindividual variation seen with bupropion and methylphe-
nidate treatments. In addition, cocaine users with the T356M poly-
morphism likely require higher doses to experience its intended effects,
which could increase the risk for toxic effects that are not mediated by
DAT inhibition, like hyperthermia, cardiotoxicity or hepatotoxicity
(Kontak et al., 2012). On the other hand, users could be less at risk for
cocaine dependence, as DA uptake is less potently inhibited.
The relevance of the difference in inhibition of DA uptake of this
polymorphism for patients using citalopram is low, as the IC50 values on
both transporters are well above the estimated brain concentration
range (Table 1). Fluoxetine also showed only a weak but equipotent
inhibition at both hDATs, in line with the primary target of SSRIs being
SERT. Moreover, our data indicate comparable inhibition of T356M
and WT hDAT (Fig. 4) by DA releasing DAT substrates MDMA, am-
phetamine and 4-FA, at IC50 values relevant for human exposure
(Table 1). Furthermore, arylcyclohexylamines ketamine and MXE in-
hibit hDAT at concentrations 100-fold higher than their primary target,
the N-methyl-D-aspartate (NMDA) receptor (Hondebrink et al., 2018).
Consequently, the minor effect of the T356M SNP on the IC50 of MXE is
likely of limited (clinical) relevance.
Attenuation of the inhibition of DA uptake by T356M hDAT com-
pared to WT hDAT may thus be specific for a select number of potent
DA reuptake inhibitors (bupropion, methylphenidate, and cocaine), as
this difference is absent for amphetamine-type stimulants, SSRIs and
arylcyclohexylamines. Elevated inhibition of DAT uptake was only seen
for the SSRI citalopram, but not for fluoxetine. Possible reasons for the
difference in inhibition by DA reuptake inhibitors for T356M hDAT
compared to WT hDAT may relate to conformational changes in a
binding domain of hDAT (S1 vs S2) and/or the existence of different
moieties in the chemical structures [i.e. ketone (= 0) group] and the
three-dimensional shape of DA reuptake inhibitors compared to other
DAT inhibitors. Future research, including 3D conformational
prediction analysis, will have to clarify whether the observed differ-
ences are due to general differences in physico-chemical properties or
to specific pharmacological properties, e.g. the potency to inhibit or the
ability to reverse DAT.
In summary, the polymorphic hDAT is differently affected by sev-
eral psychoactive substances compared to WT hDAT. Although the
prevalence of this mutation is currently unknown, such a mutation
could contribute to interindividual differences in, for example, the
treatment efficiency with psychoactive substances, but also susceptibly
for toxicity and addiction following recreational drug use.
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